Day One Biopharmaceuticals, Inc. (DAWN) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $21.50 (—)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 10, 2026 | Andrew Maldonado | H.C. Wainwright | $21.50 | 0.0% |
| Aug 1, 2024 | Alec Stranahan | Bank of America Securities | $24.00 | +11.6% |
| May 7, 2024 | Andrew Maldonado | H.C. Wainwright | $40.00 | +86.0% |
| Jan 8, 2023 | Joseph Catanzaro | Piper Sandler | $45.00 | +109.3% |
| Jun 20, 2022 | Joseph Catanzaro | Piper Sandler | $40.00 | +86.0% |
Top Analysts Covering DAWN
DAWN vs Sector & Market
| Metric | DAWN | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.42 | 2.24 | 2.41 |
| Analyst Count | 12 | 8 | 18 |
| Target Upside | +10.5% | +1150.3% | +14.9% |
| P/E Ratio | -20.74 | 6.89 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $55M | $57M | $60M | 7 |
| 2026-09-30 | $58M | $62M | $66M | 4 |
| 2026-12-31 | $63M | $67M | $72M | 4 |
| 2027-03-31 | $70M | $74M | $80M | 4 |
| 2027-06-30 | $73M | $78M | $84M | 3 |
| 2027-09-30 | $79M | $84M | $90M | 3 |
| 2027-12-31 | $82M | $87M | $94M | 3 |
| 2028-12-31 | $395M | $399M | $403M | 5 |
| 2029-12-31 | $503M | $533M | $568M | 2 |
| 2030-12-31 | $601M | $637M | $679M | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-0.22 | $-0.18 | $-0.09 | 5 |
| 2026-09-30 | $-0.18 | $-0.16 | $-0.15 | 1 |
| 2026-12-31 | $-0.17 | $-0.16 | $-0.14 | 1 |
| 2027-03-31 | $-0.20 | $-0.18 | $-0.17 | 1 |
| 2027-06-30 | $-0.19 | $-0.17 | $-0.16 | 1 |
| 2027-09-30 | $-0.15 | $-0.14 | $-0.13 | 1 |
| 2027-12-31 | $-0.15 | $-0.14 | $-0.13 | 1 |
| 2028-12-31 | $-0.05 | $0.25 | $0.99 | 6 |
| 2029-12-31 | $1.15 | $1.25 | $1.35 | 4 |
| 2030-12-31 | $1.71 | $1.85 | $2.00 | 2 |
Frequently Asked Questions
What is the analyst consensus for DAWN?
The consensus among 12 analysts covering Day One Biopharmaceuticals, Inc. (DAWN) is Buy with an average price target of $23.75.
What is the highest price target for DAWN?
The highest price target for DAWN is $45.00, set by Joseph Catanzaro at Piper Sandler on 2023-01-08.
What is the lowest price target for DAWN?
The lowest price target for DAWN is $21.50, set by Andrew Maldonado at H.C. Wainwright on 2026-03-10.
How many analysts cover DAWN?
12 analysts have issued ratings for Day One Biopharmaceuticals, Inc. in the past 12 months.
Is DAWN a buy or sell right now?
Based on 12 analyst ratings, DAWN has a consensus rating of Buy (2.42/5) with a +10.5% upside to the consensus target of $23.75.
What are the earnings estimates for DAWN?
Analysts estimate DAWN will report EPS of $-0.18 for the period ending 2026-06-30, with revenue estimated at $57M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.